U.S. Construction Stock News

Theravance Biopharma walked into this earnings print with a flat share price and a reputation built on lumpy royalty income and big one off gains. The stock barely moved today, yet the quarter itself told a quieter story. Core revenue sat at US$20.7m while the company swung to a quarterly loss of US$5.9m as earnings per share slipped back into negative territory. The real headline for you is the gap between rich trailing figures, which still carry that large past gain, and a current quarter...

Omega Healthcare Investors earnings event Omega Healthcare Investors (OHI) recently reported second quarter 2026 results, giving investors fresh detail on how this healthcare focused REIT is performing midway through the year. The report covered sales, revenue, net income and earnings per share for both the quarter and the first six months, offering a broad view of Omega Healthcare Investors financial position. See our latest analysis for Omega Healthcare Investors. At a share price of...

Why Innovative Industrial Properties Stock Is Back in Focus Innovative Industrial Properties (IIPR) recently posted second quarter 2026 earnings with net income and earnings per share higher than a year earlier, despite relatively unchanged revenue. The company also completed a sizeable share buyback. See our latest analysis for Innovative Industrial Properties. The latest earnings and completed buyback have put Innovative Industrial Properties back on investors’ radar, even as the share...

NCR Atleos (NATL) reported second quarter 2026 results on 5 August, with net income and earnings per share above the prior year. Revenue for both the quarter and half year stayed broadly similar. See our latest analysis for NCR Atleos. NCR Atleos shares trade at US$46.86, with a 1 month share price return of 4.3% and a year to date share price return of 25.9%. The 1 year total shareholder return of 27.7% points to momentum building around the earnings improvement story. If you are looking for...

Rocket Lab stock barely moved after earnings, slipping just 0.04% to about $80. That calm surface hides a real sentiment split. Bulls are pointing to record Q2 revenue of $234.1m and a backlog that management pegs at about $2.36b. Bears are focused on the ongoing net loss of $49.3m and the reminder that this is still a cash burning space player. Today's flat trading suggests investors are unsure whether to emphasize the top line results or the profitability challenges that remain. Is Rocket...

BRT Apartments stock barely flinched after earnings, slipping only 0.3% to about US$14, even though the headline story is not about profit at all. For a residential REIT, the real heartbeat is Funds From Operations, and BRT printed roughly US$5.5m in the quarter against a reported net loss of US$3.4m. The market seems to be shrugging because that contrast between cash style earnings and accounting losses is already baked in. The real question for you now is how comfortable you are with that...

SEALSQ (LAES) is back on investors’ radar after appointing Daniel Brau as Chief Quantum Officer, following its full acquisition of Swiss quantum photonics firm Miraex. This move ties leadership directly to its expanding quantum platform ambitions. See our latest analysis for SEALSQ. Despite the quantum-focused announcements in late July and early August, SEALSQ’s share price return is still down about 40% year to date and the 3 year total shareholder return has declined about 72%, which...

With the S&P 500 sitting at record levels and trading at 28 times earnings, investors are weighing strong AI driven corporate results against the risk that expectations are set too high. That mix of optimism and unease can create openings that feel easy to miss. This article walks through three large cap stocks from our U.S. index funds screener that are closely tied to this earnings story and explains how today’s setup could matter for your long term portfolio. The three stocks highlighted...

eToro Group walked into this earnings print with sentiment already frayed. The stock was down about 29% over the past three months, then dropped another 14% today to close near US$29. That kind of one day slump suggests traders are reacting emotionally to a softer second quarter revenue line rather than the full picture. The headline is that eToro still produced profitable growth, with Q2 net income of US$53.48m and basic earnings per share of US$0.65 on revenue of US$1.55b. The real question...

AECOM walked into this earnings season wearing the label of an underappreciated infrastructure play with solid long term growth credentials. Today the market slammed the stock anyway. The share price dropped 8.5% to about $67 after the company reported a quarterly loss and booked a heavy $337m pretax charge on a troubled construction management project. For investors, the headline is simple. AECOM just posted a sharp earnings hit driven by one project, while still pointing to record backlog...

Quanterix stock jumped about 8% to US$2.63 after earnings, a sharp move for a company that came into this week with double digit declines over the past month. The market is reacting to a very different story compared with the old high growth diagnostics promise. The headline this quarter is margin and cash discipline. Quanterix posted Q2 revenue of US$32.9 million while reporting a sizeable net loss and cutting full year revenue guidance to a range of US$142 million to US$148 million. The...

Cardinal Health entered this earnings week on a strong run, with the stock already up over the past quarter and edging another 1.3% higher to about US$240 by the close. The market reaction was positive but restrained for a distributor that just printed adjusted free cash flow of US$5.0b and full year revenue of US$254b. That gap between a modest price move and very large cash generation is the real story for you as a shareholder. Is Cardinal Health a rare case where a rich P/E and heavy debt...

Motorcar Parts of America walked into this earnings season with a stock that had drifted down in recent weeks and then barely budged on the print, closing up just 0.2% at US$12.45. That muted move masks a jarring headline. The company swung from a recent quarterly profit to a loss of US$13.4m in Q1 on revenue of US$168.0m. For an auto parts supplier that many investors view as a recovery and margin story, this quarter puts the squeeze in full view. The rest of the year now has to answer...

Oil prices remain sensitive to events in the Middle East, which keeps inflation expectations and defense priorities in focus for governments that rely on energy imports. That backdrop draws attention to companies in the Aerospace and Defense screener, which sit close to major spending decisions. For investors who do not want to sit on the sidelines, this article highlights 3 stocks from the screener that may warrant closer examination. The 3 Aerospace and Defense stocks below are just a...

Accendra Health stock closed at US$1.26, down 10% on the day, as investors reacted to another quarter in the red. The headline is not the revenue line. The real story is the squeeze in profitability, with Q2 basic earnings per share at a loss of US$1.16 and net income excluding extra items also in loss territory. For a home based health provider already dealing with high volatility and balance sheet pressure, that profit strain matters more than the single-day move. The key question now is...

AirSculpt Technologies just jumped 16.9% to about US$3.22, even though this stock has spent the past three months grinding lower. The spark was not a clean return to profits. It was a margin story in a turnaround quarter. Q2 revenue landed at US$42.9 million, while adjusted earnings before interest, tax, depreciation and amortization came in at US$4.9 million with gross margin around 61%. For a business still posting losses, that level of gross profitability is what the market latched onto...

IDEXX Laboratories (NasdaqGS:IDXX) has launched the Catalyst proBNP Test, the first dual-species point-of-care NT-proBNP cardiac assay for companion animals. The new test enables real-time cardiac assessment for both dogs and cats at veterinary clinics. The Catalyst proBNP Test expands IDEXX Laboratories' in-clinic diagnostic menu for cardiac disease in pets. This move into real-time cardiac diagnostics at the clinic level fits into a broader shift toward data driven tools in animal and...

Fluent came into this earnings print as a high risk, low multiple ad tech stock that had quietly rallied over the past quarter. The stock slipped 3.5% to US$4.12 after the release, even though Q2 showed Commerce Media Solutions revenue of US$30.5 million and a return to year over year growth for the overall business. Losses persisted, with basic earnings per share still in the red. This keeps the focus squarely on whether this new commerce media mix can carry Fluent closer to sustainable...

CECO Environmental stock jumped about 5% today to US$73.97, even though the headline earnings number showed a loss for the quarter. The market is reacting to something bigger than a single reported earnings per share figure. The key story is the margin picture. CECO Environmental reported record quarterly revenue of US$284.961m and adjusted earnings before interest, tax, depreciation and amortisation margins in the mid teens for the first time. That appears to have helped pull the stock out...

With the Strait of Hormuz back in the headlines and Brent crude at $88.91 a barrel, energy risk is once again front and center for global markets. Sudden supply scares can reshuffle where money flows in the oil and gas space, creating both potential openings and traps. This article explains how the latest flashpoint could matter for your portfolio and profiles 3 large oil and gas producers that are closely exposed to this news. The three producers that follow are just a starting sample, and...

Esquire Financial Holdings stock added 3% today to close at US$132.92. Yet the real story sits in the earnings tape. Q2 delivered US$1.60 in adjusted earnings per share and a return on equity above 18%. The market seemed to cheer another clean quarter from a premium valued bank without fully wrestling with what that combination of strong profitability and a higher P/E multiple now implies. Love Esquire Financial Holdings' 18% plus return on equity but wondering how its premium P/E stacks up...

Why Custom Truck One Source stock is back on investors’ radar Custom Truck One Source (CTOS) is drawing attention after reporting a return to profitability in the second quarter of 2026, alongside raised full year guidance and continued strength in transmission and distribution demand. See our latest analysis for Custom Truck One Source. Custom Truck One Source’s share price has eased slightly in the past week, yet the 90 day share price return of 7.26% and year to date share price return of...

N-able stock slipped 1.9% to US$3.15 into the close, which is a muted reaction to an earnings print that puts sentiment, not the income statement, in the spotlight. The headline is simple: solid recurring revenue and margin metrics met a sharply lower full year growth guide as management reset expectations around a go to market transition and renewal pressure in key security tools. For you as an investor, the emotional tug of a low share price sits against a software business posting about...

The market clipped Axsome Therapeutics by 2.3% today, even though the story on the income statement is far from simple. Axsome came into this earnings print after a choppy three months for the stock and reported US$218.4m in Q2 revenue, led by fast building neurology brands. The company still posted a quarterly net loss of US$51.3m, which keeps nerves high around profitability. For investors, the question is whether today’s modest share price pullback is sensible caution about ongoing losses...